Gene therapy can include efforts to fix dysfunctional genes or to deliver DNA to a target cell. One way to deliver DNA is to use viral vectors – viruses that don’t cause disease in humans – that have been engineered to efficiently deposit their genetic information in targeted human cells.
Recombinant adeno-associated viruses (AAVs) have become the viral vectors of choice for many gene therapy applications due to their history of low immunogenicity and good clinical outcomes.
- Improving AAV yield and purity using affinity resins
- How affinity purification can contribute to viral clearance
